Actively Recruiting
Selective Coronary Revascularization in Carotid Artery Disease Patients After Carotid Revascularization (SCORECAD Trial)
Led by Pauls Stradins Clinical University Hospital · Updated on 2024-08-09
300
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to determine whether among symptomatic and asymptomatic carotid artery stenosis (CAS) patients with no known coronary artery disease (CAD) who had undergone carotid artery revascularization (endarterectomy of stenting) a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.
CONDITIONS
Official Title
Selective Coronary Revascularization in Carotid Artery Disease Patients After Carotid Revascularization (SCORECAD Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent before any study activities
- Age 50 years or older with symptomatic or asymptomatic critical carotid stenosis successfully treated by carotid endarterectomy or stenting within the past 14 days
- Willing and able to have a coronary CT angiography scan within 14 days of randomization and agree to submit data for FFRct analysis
You will not qualify if you...
- Known coronary artery disease, prior heart attack, or previous coronary revascularization (PCI or CABG)
- Had coronary angiography or coronary CT angiography before randomization
- History of 2nd or 3rd degree heart block, sick sinus syndrome, or long QT syndrome
- Severe asthma or severe/bronchodilator-dependent chronic obstructive pulmonary disease (COPD)
- Severe congestive heart failure (NYHA class III or IV)
- Severe arrhythmia or previous pacemaker or defibrillator implantation
- Impaired kidney function with estimated GFR below 30 ml/min
- Known severe allergy to iodinated contrast
- Pregnancy or unknown pregnancy status in women of childbearing potential
- Evidence of active clinical instability such as sudden acute chest pain, cardiogenic shock, unstable low blood pressure, or acute pulmonary edema
- Any serious life-threatening disease with life expectancy under 2 years
- Any active infection
- Unable to follow study procedures
- Contraindications to long-term antiplatelet or anticoagulation therapy after PCI or CABG
- Large neurological deficit with Rankin scale above III
- Participation in another interventional clinical study within 30 days before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pauls Stradins Clinical University Hospital
Riga, Latvia
Actively Recruiting
Research Team
D
Dainis Krievins, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here